EYPT Q4 2019 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+253.5% YoY

Gross Profit

$7M84.7% margin

Operating Income

-$9M-104.1% margin

Net Income

-$10M-120.6% margin

EPS (Diluted)

$-0.98

QoQ Revenue Growth

+244.1%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$857,000

Balance Sheet

Total Assets

$73M

Total Liabilities

$65M

Stockholders' Equity

$8M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$2M	+253.5%
Gross Profit	$7M	-$2M	+520.8%
Operating Income	-$9M	-$11M	+18.4%
Net Income	-$10M	-$12M	+10.2%

Revenue Segments

Y U T I Q Product

$5M60%

D E X Y C U Product

$3M40%